Thelansis

 Prostate cancer, characterized by its lengthy disease trajectory and diverse clinical outcomes among individual patients, predominantly affects men aged 45 to 60. Risk factors associated with this cancer encompass familial predisposition, ethnicity, age, obesity, and various environmental influences, with familial inheritance being a significant genetic risk factor. The majority of newly diagnosed prostate cancer cases initially present with localized disease, typically managed through radical prostatectomy and radiation therapy, followed by androgen deprivation therapy (ADT). However, within a decade, a variable percentage of patients progress to castration-resistant prostate cancer (CRPC). Among them, those with metastatic castration-resistant prostate cancer (MCRPC) face a particularly grim prognosis, with median survival ranging from 9 to 30 months for CRPC and reduced to 9–13 months for MCRPC. Current therapeutic strategies for MCRPC include cytotoxic chemotherapy agents, and...

  Prostate cancer (PCa) is one of the most prevalent malignancies globally. Most men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the cancer grade, a variable percentage of these patients experience castration-resistant prostate cancer (CRPC) progression within ten years. Metastatic castration-resistant prostate cancer (MCRPC) patients remain incurable, and the prognosis of these patients is relatively poor. For men with CRPC, the median survival ranges from 9 to 30 months, and for those with MCRPC, this survival is reduced to 9–13 months. Currently, cytotoxic chemotherapy agents, AR blocking agents, immunotherapies, and radiopharmaceuticals represent effective therapeutic strategies for MCRPC treatment. Taxane chemotherapy (docetaxel and cabazitaxel) is the standard for MCRPC treatment. The incidence of cases of Prostate cancer (PCa) ranges f...

  Prostate cancer (PCa) is one of the most prevalent malignancies globally. Most men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the cancer grade, a variable percentage of these patients experience castration-resistant prostate cancer (CRPC) progression within ten years. Metastatic castration-resistant prostate cancer (MCRPC) patients remain incurable, and the prognosis of these patients is relatively poor. For men with CRPC, the median survival ranges from 9 to 30 months, and for those with MCRPC, this survival is reduced to 9–13 months. Currently, cytotoxic chemotherapy agents, AR blocking agents, immunotherapies, and radiopharmaceuticals represent effective therapeutic strategies for MCRPC treatment. Taxane chemotherapy (docetaxel and cabazitaxel) is the standard for MCRPC treatment.   Prostate cancer (PCa) incidence ranges from 95 to 112 ...